C. Regan

发表

Salt-induced hypertension in normotensive spontaneously hypertensive rats.

J. M. Wyss, S. Roysommuti, K. King, 1994, Hypertension.

Combining an in silico proarrhythmic risk assay with a tPKPD model to predict QTc interval prolongation in the anesthetized guinea pig assay

S. Polak, B. Rodríguez, C. Regan, 2020, Toxicology and applied pharmacology.

Calcitonin Gene-Related Peptide Receptor Antagonism Does Not Affect the Severity of Myocardial Ischemia during Atrial Pacing in Dogs with Coronary Artery Stenosis

C. Regan, J. Lynch, G. Stump, 2009, Journal of Pharmacology and Experimental Therapeutics.

An improved automated method to quantitate infarct volume in triphenyltetrazolium stained rat brain sections.

C. Regan, J. Lynch, H. Regan, 2007, Journal of pharmacological and toxicological methods.

Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics.

K. K. Nanda, C. Lindsley, R. Spencer, 2017, Bioorganic & medicinal chemistry letters.

MK-0448, a Specific Kv1.5 Inhibitor: Safety, Pharmacokinetics, and Pharmacodynamic Electrophysiology in Experimental Animal Models and Humans

W. Kraft, H. Greenberg, C. Regan, 2012, Circulation. Arrhythmia and electrophysiology.

In Vivo Cardiac Electrophysiologic Effects of a Novel Diphenylphosphine Oxide IKur Blocker, (2-Isopropyl-5-methylcyclohexyl) Diphenylphosphine Oxide, in Rat and Nonhuman Primate

C. Regan, C. Atkins, J. Lynch, 2006, Journal of Pharmacology and Experimental Therapeutics.

Early, short-term treatment with captopril permanently attenuates cardiovascular changes in spontaneously hypertensive rats.

S. Bishop, C. Regan, K. Berecek, 1997, Clinical and experimental hypertension.

Pressure-independent effects of AT1-receptor antagonism on cardiovascular remodeling in aortic-banded rats.

S. Bishop, C. Regan, K. Berecek, 1997, The American journal of physiology.

Captopril prevents vascular and fibrotic changes but not cardiac hypertrophy in aortic-banded rats.

S. Bishop, C. Regan, K. Berecek, 1996, The American journal of physiology.

Pharmacological Properties of MK-3207, a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist

J. Vacca, C. Regan, Y. S. Tang, 2010, Journal of Pharmacology and Experimental Therapeutics.

Attenuation of edema and infarct volume following focal cerebral ischemia by early but not delayed administration of a novel small molecule KDR kinase inhibitor

K. Foster, C. Regan, K. Rickert, 2009, Neuroscience Research.

Development of a Smooth Muscle–Targeted Cre Recombinase Mouse Reveals Novel Insights Regarding Smooth Muscle Myosin Heavy Chain Promoter Regulation

G. Owens, I. Manabe, C. Regan, 2000, Circulation research.

Smooth Muscle–Targeted Knockout of Connexin43 Enhances Neointimal Formation in Response to Vascular Injury

G. Owens, I. Manabe, B. Duling, 2007, Arteriosclerosis, thrombosis, and vascular biology.

Effect of Calcitonin Gene-Related Peptide Receptor Antagonism on the Systemic Blood Pressure Responses to Mechanistically Diverse Vasomodulators in Conscious Rats

C. Regan, J. Lynch, S. Kane, 2010, Journal of cardiovascular pharmacology.

Positive- and negative-acting Kruppel-like transcription factors bind a transforming growth factor beta control element required for expression of the smooth muscle cell differentiation marker SM22alpha in vivo.

G. Owens, C. Regan, P. Adam, 2000, The Journal of biological chemistry.

Hemodynamic and Cardiac Neurotransmitter-releasing Effects in Conscious Dogs of Attention- and Wake-promoting Agents: A Comparison of d-Amphetamine, Atomoxetine, Modafinil, and a Novel Quinazolinone H3 Inverse Agonist

J. Renger, P. Tannenbaum, C. Regan, 2009, Journal of cardiovascular pharmacology.

Development of ProTx-II Analogues as Highly Selective Peptide Blockers of Nav1.7 for the Treatment of Pain.

D. Henze, S. Grauer, A. Palani, 2021, Journal of medicinal chemistry.

Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor

E. Hostetler, C. Regan, M. Fraley, 2020, The Journal of Pharmacology and Experimental Therapeutics.

Atrial Antifibrillatory Effects of Structurally Distinct IKur Blockers 3-[(Dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-Phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in Dogs with Underlying Heart Failure

N. Liverton, L. Kiss, C. Regan, 2008, Journal of Pharmacology and Experimental Therapeutics.

Novel Method to Assess Cardiac Electrophysiology in the Rat: Characterization of Standard Ion Channel Blockers

Rena Zhang, C. Regan, J. Lynch, 2005, Journal of cardiovascular pharmacology.

In Vivo Antiarrhythmic and Cardiac Electrophysiologic Effects of a Novel Diphenylphosphine Oxide I Kur Blocker, DPO-1

C. Regan, J. Lynch, G. Stump, 2005 .

Comparison of the Intrinsic Vasorelaxant and Inotropic Effects of the Antiarrhythmic Agents Vernakalant and Flecainide in Human Isolated Vascular and Cardiac Tissues

C. Regan, G. Gleim, J. Lynch, 2013, Journal of cardiovascular pharmacology.

In Vivo Cardiac Electrophysiologic and Antiarrhythmic Effects of an Isoquinoline IKur Blocker, ISQ-1, in Rat, Dog, and Nonhuman Primate

Kenneth D Anderson, N. Liverton, C. Regan, 2007, Journal of cardiovascular pharmacology.

Selective Expression of an Endogenous Inhibitor of FAK Regulates Proliferation and Migration of Vascular Smooth Muscle Cells

J. Parsons, G. Owens, C. Regan, 2001, Molecular and Cellular Biology.

Association of respiratory failure with inhibition of NaV1.6 in the phrenic nerve

D. Henze, C. Regan, Yuxing Li, 2022, Channels.

Cardiac drug-drug interaction between HCV-NS5B pronucleotide inhibitors and amiodarone is determined by their specific diastereochemistry

Christopher Brynczka, K. Koeplinger, C. Regan, 2017, Scientific Reports.

Comparison of the Vasoconstrictor Effects of the Calcitonin Gene-related Peptide Receptor Antagonist Telcagepant (MK-0974) and Zolmitriptan in Human Isolated Coronary Arteries

R. Hargreaves, L. Edvinsson, C. Regan, 2010, Journal of cardiovascular pharmacology.

Assessment of the clinical cardiac drug‐drug interaction associated with the combination of hepatitis C virus nucleotide inhibitors and amiodarone in guinea pigs and rhesus monkeys

C. Regan, Jianzhong Wen, P. Morissette, 2016, Hepatology.

Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation.

Kenneth D Anderson, K. K. Nanda, N. Liverton, 2006, Journal of medicinal chemistry.

Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation

Craig W. Lindsley, William J. Ray, Michelle Pearson, 2009, Proceedings of the National Academy of Sciences.

Correction for d'Errico et al., Additional evidence on the use of personal ornaments in the Middle Paleolithic of North Africa

S. Doran, W. Shipe, M. Seager, 2009, Proceedings of the National Academy of Sciences.

Lack of Protection with a Novel, Selective Melanocortin Receptor Subtype-4 Agonist RY767 in a Rat Transient Middle Cerebral Artery Occlusion Stroke Model

R. Nargund, C. Regan, J. Lynch, 2008, Pharmacology.

Block of Peripheral Nerve Sodium Channels Selectively Inhibits Features of Neuropathic Pain in Rats

O. McManus, J. W. Tarpley, Z. Ali, 2006, Molecular Pharmacology.

In Vivo Antiarrhythmic and Cardiac Electrophysiologic Effects of a Novel Diphenylphosphine Oxide IKur Blocker (2-Isopropyl-5-methylcyclohexyl) Diphenylphosphine Oxide

C. Regan, J. Lynch, G. Stump, 2005, Journal of Pharmacology and Experimental Therapeutics.

Molecular mechanisms of decreased smooth muscle differentiation marker expression after vascular injury.

G. Owens, C. Regan, P. Adam, 2000, The Journal of clinical investigation.

Interaction of CArG Elements and a GC-rich Repressor Element in Transcriptional Regulation of the Smooth Muscle Myosin Heavy Chain Gene in Vascular Smooth Muscle Cells*

G. Owens, C. Regan, C S Madsen, 1997, The Journal of Biological Chemistry.

Positive- and Negative-acting Krüppel-like Transcription Factors Bind a Transforming Growth Factor β Control Element Required for Expression of the Smooth Muscle Cell Differentiation Marker SM22α in Vivo *

Christopher P. Regan, G. Owens, C. Regan, 2000, The Journal of Biological Chemistry.

Smooth muscle-specific expression of the smooth muscle myosin heavy chain gene in transgenic mice requires 5'-flanking and first intronic DNA sequence.

G. Owens, I. Manabe, C. Regan, 1998, Circulation research.

Positive- and Negative-acting Krüppel-like Transcription Factors Bind a Transforming Growth Factor b Control Element Required for Expression of the Smooth Muscle Cell Differentiation Marker SM22a in Vivo*

G. Owens, C. Regan, P. Adam, 2000 .

Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel.

N. Liverton, C. Claiborne, R. Spencer, 2010, Bioorganic & medicinal chemistry letters.

Effects of the prototype serotonin 5-HT(1B/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37) on myocardial reactive hyperemic response in conscious dogs.

Kenneth D Anderson, C. Regan, R. Gould, 2009, European journal of pharmacology.

The Prototype Serotonin 5-HT1B/1D Agonist Sumatriptan Increases the Severity of Myocardial Ischemia During Atrial Pacing in Dogs With Coronary Artery Stenosis

C. Regan, J. Lynch, G. Stump, 2009, Journal of cardiovascular pharmacology.

Potent antagonists of the Kv1.5 potassium channel: synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3-yl)acetamides.

K. K. Nanda, C. Lindsley, R. Spencer, 2006, Bioorganic & medicinal chemistry letters.

Transgenic Mice Requires 5 Specific Expression of the Smooth Muscle Myosin Heavy Chain Gene in − Smooth Muscle

G. Owens, I. Manabe, C. Regan, 1998 .

Attenuation of scratch‐induced reactive astrogliosis by novel EphA4 kinase inhibitors

Sujata Sharma, Hemaka A. Rajapakse, J. Vacca, 2011, Journal of neurochemistry.

Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects

Wei Li, M. Su, S. Spatz, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Development and characterization of canine‐specific computational models to predict pulsatile arterial hemodynamics and ventricular‐arterial coupling

C. Regan, J. Chirinos, H. Regan, 2023, Physiological reports.

Chapter 6 – Animal Models for Cardiovascular Research

C. Regan, R. Shannon, You-tang Shen, 2017 .

Characterization of an investigative safety pharmacology model to assess comprehensive cardiac function and structure in chronically instrumented conscious beagle dogs.

C. Regan, F. Sannajust, J. Degeorge, 2016, Journal of pharmacological and toxicological methods.

QT interval correction assessment in the anesthetized guinea pig.

C. Regan, P. Morissette, F. Sannajust, 2015, Journal of pharmacological and toxicological methods.

Long term assessment of blood pressure transducer drift in rhesus monkeys chronically instrumented with telemetry implants.

C. Regan, J. Lynch, H. Regan, 2009, Journal of pharmacological and toxicological methods.

Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist.